Work

A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors

Year: 2012

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-012-9881-z

Authors: Geoffrey I. Shapiro, Stewart McCallum, Laurel M. Adams, Laurie Sherman, Steve Weller, Suzanne Swann, Harold Keer, Dale Miles, Thomas Müller, Patricia LoRusso

Institutions: Harvard University, Dana-Farber Cancer Institute, GlaxoSmithKline (United States), Exelixis (United States), The Barbara Ann Karmanos Cancer Institute

Language: English

Topic: Cancer Mechanisms and Therapy

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: GlaxoSmithKline, Exelixis

OpenAlex ID: W4236481024

FWCI: 3.959

Cites: 27

Cited by: 48

Related to: 10